Aclaris Therapeutics, Inc. (ACRS)
Largest Insider Buys in Sector
ACRS Stock Price History Chart
ACRS Stock Performance
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Activity of Aclaris Therapeutics, Inc.
Over the last 12 months, insiders at Aclaris Therapeutics, Inc. have bought $2.6M and sold $74,355 worth of Aclaris Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aclaris Therapeutics, Inc. have bought $1.35M and sold $5.94M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $14.46M. Loerop James (Chief Business Officer) — $199,917. Balthaser Kevin (Chief Financial Officer) — $74,971.
The last purchase of 50,000 shares for transaction amount of $56,505 was made by Leonard Braden Michael (10 percent owner) on 2024‑06‑18.
List of Insider Buy and Sell Transactions, Aclaris Therapeutics, Inc.
| 2024-06-18 | Leonard Braden Michael | 10 percent owner | 50,000 0.0708% | $1.13 | $56,505 | +7.96% | ||
| 2024-06-17 | Leonard Braden Michael | 10 percent owner | 150,000 0.2124% | $1.13 | $169,500 | +1.77% | ||
| 2024-06-14 | Leonard Braden Michael | 10 percent owner | 345,000 0.5039% | $1.17 | $402,201 | -3.39% | ||
| 2024-06-13 | Leonard Braden Michael | 10 percent owner | 528,621 0.7614% | $1.15 | $607,757 | -3.36% | ||
| 2024-06-12 | Leonard Braden Michael | 10 percent owner | 82,579 0.1179% | $1.14 | $94,140 | +1.30% | ||
| 2024-06-11 | Leonard Braden Michael | 10 percent owner | 1M 1.3531% | $1.08 | $1.08M | +2.68% | ||
| 2024-03-04 | Powell Andrew Kenneth William | director | 6,000 0.0083% | $1.25 | $7,500 | -4.80% | ||
| 2024-03-01 | Powell Andrew Kenneth William | director | 8,500 0.0119% | $1.23 | $10,455 | -3.25% | ||
| 2023-10-23 | Sale | Monahan Joseph | Chief Scientific Officer | 6,000 0.0086% | $5.08 | $30,460 | -76.31% | |
| 2023-09-06 | Balthaser Kevin | Chief Financial Officer | 9,490 0.014% | $7.90 | $74,971 | -84.11% | ||
| 2023-08-28 | Loerop James | Chief Business Officer | 14,705 0.0214% | $6.80 | $99,959 | -81.82% | ||
| 2023-08-21 | Sale | Monahan Joseph | Chief Scientific Officer | 6,000 0.0084% | $7.32 | $43,895 | -83.52% | |
| 2023-06-20 | Sale | Monahan Joseph | Chief Scientific Officer | 6,000 0.0087% | $10.28 | $61,663 | -88.42% | |
| 2023-03-17 | Manion Douglas J. | Pres and CEO | 6,300 0.0094% | $7.86 | $49,532 | -12.55% | ||
| 2023-03-09 | Manion Douglas J. | Pres and CEO | 6,500 0.0098% | $7.74 | $50,278 | -3.79% | ||
| 2023-03-03 | Sale | Walker Neal | director | 30,240 0.0447% | $12.63 | $382,070 | -41.47% | |
| 2023-03-03 | Sale | Monahan Joseph | Chief Scientific Officer | 16,037 0.0237% | $12.63 | $202,615 | -41.47% | |
| 2023-03-03 | Sale | Balthaser Kevin | Chief Financial Officer | 894 0.0013% | $12.63 | $11,290 | -41.47% | |
| 2023-03-02 | Sale | Walker Neal | director | 29,000 0.0425% | $12.37 | $358,588 | -40.65% | |
| 2023-03-02 | Sale | Monahan Joseph | Chief Scientific Officer | 14,800 0.0217% | $12.37 | $183,024 | -40.65% |
Insider Historical Profitability
| Leonard Braden Michael | 10 percent owner | 11552134 15.4454% | $1.12 | 6 | 0 | |
| Monahan Joseph | Chief Scientific Officer | 129724 0.1831% | $1.12 | 0 | 12 | |
| Loerop James | Chief Business Officer | 21688 0.0306% | $1.12 | 1 | 1 | |
| Balthaser Kevin | Chief Financial Officer | 15461 0.0218% | $1.12 | 1 | 2 | |
| Powell Andrew Kenneth William | director | 28863 0.0007% | $1.12 | 3 | 0 | <0.0001% |
| CHA ALBERT | director | 4191397 5.917% | $1.12 | 2 | 0 | +71.55% |
| FMR LLC | 10 percent owner | 2571354 3.63% | $1.12 | 1 | 1 | +61.56% |
| Sofinnova Venture Partners VIII, L.P. | 10 percent owner | 2289480 3.2321% | $1.12 | 1 | 0 | +61.56% |
| RA CAPITAL MANAGEMENT, LLC | 10 percent owner | 2102169 2.9676% | $1.12 | 17 | 2 | +27.75% |
| Mehra Anand | director | 1911573 2.6986% | $1.12 | 2 | 1 | +4.44% |
| Walker Neal | director | 1273202 1.7974% | $1.12 | 1 | 11 | <0.0001% |
| Flynn James E | 10 percent owner | 964101 1.361% | $1.12 | 0 | 7 | |
| SCHIFF ANDREW N | director | 434455 0.6133% | $1.12 | 1 | 12 | <0.0001% |
| Ruffo Frank | Chief Financial Officer | 201883 0.285% | $1.12 | 2 | 6 | <0.0001% |
| Tullman Stephen A. | director | 177457 0.2505% | $1.12 | 4 | 0 | <0.0001% |
| Gordon David N. | Chief Medical Officer | 147447 0.2082% | $1.12 | 0 | 3 | |
| Ali-Jackson Kamil | Chief Legal Officer | 122196 0.1725% | $1.12 | 0 | 14 | |
| VIVO VENTURES VII, LLC | 10 percent owner | 60972 0.0861% | $1.12 | 2 | 5 | +71.55% |
| Manion Douglas J. | Pres and CEO | 12800 0.0181% | $1.12 | 2 | 0 | <0.0001% |
| Molineaux Christopher P. | director | 7682 0.0108% | $1.12 | 0 | 1 |
Institutional Investor Ownership
| Bml Capital Management Llc | $11.65M | 13.19 | 9.4M | +1,338.65% | +$10.84M | 8.87 | |
| BlackRock | $6.45M | 7.3 | 5.2M | -11.92% | -$872,618.69 | <0.0001 | |
| The Vanguard Group | $6.11M | 6.92 | 4.93M | +4.39% | +$257,198.32 | <0.0001 | |
| D. E. Shaw & Co. | $4.07M | 4.61 | 3.28M | +69.31% | +$1.67M | 0.01 | |
| Millennium Management LLC | $4.06M | 4.59 | 3.27M | -5.92% | -$255,277.55 | <0.01 | |
| Bain Capital Life Sciences Investors Llc | $3.72M | 4.21 | 3M | -14.29% | -$620,000.00 | 0.37 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $3.41M | 3.86 | 2.75M | -8.17% | -$303,800.02 | 0.09 | |
| Acadian Asset Management | $2.65M | 3 | 2.14M | -9.19% | -$267,701.92 | 0.01 | |
| Renaissance Technologies | $2.08M | 2.35 | 1.67M | -4.18% | -$90,558.98 | <0.01 | |
| Geode Capital Management | $1.94M | 2.2 | 1.57M | +12.31% | +$212,686.95 | <0.0001 | |
| Two Sigma Advisers LP | $1.8M | 2.04 | 1.45M | +2.12% | +$37,324.00 | <0.01 | |
| State Street | $1.66M | 1.88 | 1.34M | -3.6% | -$61,999.99 | <0.0001 | |
| Two Sigma | $1.65M | 1.87 | 1.33M | -9.15% | -$165,967.82 | <0.01 | |
| Qube Research & Technologies | $1.5M | 1.7 | 1.21M | -27.84% | -$579,879.65 | <0.01 | |
| Deutsche Bank | $1.19M | 1.34 | 957,021 | +2.46% | +$28,489.00 | <0.01 | |
| Citadel Advisors LLC | $1.15M | 1.31 | 930,003 | -82.74% | -$5.53M | <0.01 | |
| Samsara Biocapital Llc | $863,252.00 | 0.98 | 696,171 | 0% | +$0 | 0.14 | |
| Gsa Capital Partners Llp | $842,000.00 | 0.95 | 679,137 | -57.23% | -$1.13M | 0.07 | |
| Fidelity Investments | $833,067.00 | 0.94 | 671,828 | +0.17% | +$1,381.36 | <0.0001 | |
| AQR Capital | $759,134.00 | 0.86 | 612,205 | New | +$759,134.00 | <0.01 | |
| Palo Alto Investors Lp | $706,592.00 | 0.8 | 569,832 | New | +$706,592.00 | 0.08 | |
| Northern Trust | $697,157.00 | 0.79 | 562,224 | -14.77% | -$120,791.99 | <0.0001 | |
| Morgan Stanley | $609,665.00 | 0.69 | 491,666 | -49.62% | -$600,423.29 | <0.0001 | |
| Acuitas Investments, LLC | $572,462.00 | 0.65 | 461,663 | New | +$572,462.00 | 0.3 | |
| Aisling Capital Management LP | $538,724.00 | 0.61 | 434,455 | 0% | +$0 | 0.19 | |
| Charles Schwab | $519,974.00 | 0.59 | 419,334 | -3.9% | -$21,075.03 | <0.0001 | |
| Jane Street Capital | $411,358.00 | 0.47 | 331,740 | +27.89% | +$89,721.53 | <0.0001 | |
| Hightower Advisors | $386,000.00 | 0.44 | 312,614 | -8.87% | -$37,548.73 | <0.01 | |
| Ohio Strs | $328,000.00 | 0.37 | 264,700 | +37.15% | +$88,846.24 | <0.01 | |
| Frazier Life Sciences Management L P | $327,827.00 | 0.37 | 264,377 | 0% | +$0 | 0.02 | |
| Man Group Plc | $307,117.00 | 0.35 | 247,675 | +144.54% | +$181,529.80 | <0.01 | |
| BNY Mellon | $288,636.00 | 0.33 | 232,771 | -17.57% | -$61,503.99 | <0.0001 | |
| Nuveen | $206,653.00 | 0.23 | 166,656 | -62.12% | -$338,823.08 | <0.0001 | |
| Goldman Sachs | $180,807.00 | 0.21 | 145,812 | -72.01% | -$465,084.63 | <0.0001 | |
| Group One Trading | $165,950.00 | 0.19 | 133,831 | +73.35% | +$70,221.01 | 0.01 | |
| Xtx Topco Ltd | $152,644.00 | 0.17 | 123,100 | -67.46% | -$316,448.00 | 0.01 | |
| Susquehanna International Group | $153,090.00 | 0.17 | 123,460 | -19.63% | -$37,384.66 | <0.0001 | |
| T. Rowe Price | $137,000.00 | 0.15 | 109,767 | +1.15% | +$1,562.62 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $124,959.00 | 0.14 | 100,773 | New | +$124,959.00 | <0.0001 | |
| RhumbLine Advisers | $120,545.00 | 0.14 | 97,220 | +1.53% | +$1,822.68 | <0.0001 | |
| Dimensional Fund Advisors | $110,435.00 | 0.13 | 89,061 | -52.51% | -$122,129.37 | <0.0001 | |
| Tealwood Asset Management | $104,134.00 | 0.12 | 83,979 | New | +$104,134.00 | 0.02 | |
| Deuterium Capital Management Llc | $99,191.00 | 0.11 | 79,993 | New | +$99,191.00 | 0.19 | |
| UBS | $87,297.00 | 0.1 | 70,401 | +258.75% | +$62,963.31 | <0.0001 | |
| JPMorgan Chase | $86,388.00 | 0.1 | 69,668 | +0.14% | +$117.80 | <0.0001 | |
| Barclays | $85,000.00 | 0.1 | 68,266 | -61.2% | -$134,041.91 | <0.0001 | |
| Ameriprise Financial | $78,087.00 | 0.09 | 62,974 | -2.76% | -$2,214.62 | <0.0001 | |
| Russell Investments Group Ltd | $77,837.00 | 0.09 | 62,772 | +5,265.13% | +$76,386.21 | <0.0001 | |
| AllianceBernstein | $74,896.00 | 0.09 | 60,400 | 0% | +$0 | <0.0001 | |
| BBR Partners | $74,400.00 | 0.08 | 60,000 | New | +$74,400.00 | 0.01 |